Deregulation of Angiopoietin-Like 4 Slows Ovarian Cancer Progression Through Vascular Endothelial Growth Factor Receptor 2 Phosphorylation

2020 ◽  
Author(s):  
Yuxian Wu ◽  
Xiaojun Liu ◽  
Hao Sun ◽  
Jinghai Gao ◽  
Zhijun Jin
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Progression ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals Vascular endothelial growth factor correlation with clinicopathological parameters in ovarian cancer

2019 ◽  
Vol 8 (4) ◽  
pp. 1700
Author(s):  
Mahy Egiz ◽  
Alaa Masoud ◽  
Hamed Ellakwa ◽  
Mohamed Adel Elsayed
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Progression ◽  
Clinicopathological Parameters ◽  
Vascular Endothelial ◽  
Variable Parameters ◽  
Gynecology And Obstetrics ◽  
Endothelial Growth Factor

Epithelial ovarian cancer (EOC) is one of the most lethal gynaecologic malignancies with an increasing incidence worldwide; there is an increasing need for the identification of novel prognostic biomarkers in EOC patients. Given the key role of angiogenesis and growth factors in the biology of tumorigenesis, vascular endothelial growth factor (VEGF) is considered a milestone in the process of ovarian cancer progression and invasiveness. Authors aimed in the present study to evaluate the relevance of serum level of VEGF with clinicopathological parameters in patients with EOC. VEGF is reported to be correlated with variable parameters in EOC patients including International Federation of Gynecology and Obstetrics (FIGO) classification, lymph nodal involvement and ascites formation. In the following review, authors discussed these correlations and distinguished the possible future role of VEGF as a promising prognostic biomarker for EOC patients.

Sign in / Sign up

Export Citation Format

Share Document